Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial
Authors:
- Kathleen M. SchmaindaKSKathleen M. Schmainda
- Zheng ZhangZZZheng Zhang
- Melissa PrahMPMelissa Prah
- Bradley S. SnyderBSBradley S. Snyder
- Mark R. GilbertMGMark R. Gilbert
- A. Gregory SorensenASA. Gregory Sorensen
- Daniel P. BarboriakDBDaniel P. Barboriak
- Jerrold L. BoxermanJBJerrold L. Boxerman
Open Access
- 2 February 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 17 (8) , 1148-1156
Abstract
The study goal was to determine whether changes in relative cerebral blood volume (rCBV) derived from dynamic susceptibility contrast (DSC) MRI are predictive of overall survival (OS) in patients with recurrent glioblastoma multiforme (GBM) when measured 2, 8, and 16 weeks after treatment initiation. Patients with recurrent GBM (37/123) enrolled in ACRIN 6677/RTOG 0625, a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide, consented to DSC-MRI plus conventional MRI, 21 with DSC-MRI at baseline and at least 1 postbaseline scan. Contrast-enhancing regions of interest were determined semi-automatically using pre- and postcontrast T1-weighted images. Mean tumor rCBV normalized to white matter (nRCBV) and standardized rCBV (sRCBV) were determined for these regions of interest. The OS rates for patients with positive versus negative changes from baseline in nRCBV and sRCBV were compared using Wilcoxon rank-sum and Kaplan–Meier survival estimates with log-rank tests. Patients surviving at least 1 year (OS-1) had significantly larger decreases in nRCBV at week 2 (P = .0451) and sRCBV at week 16 (P = .014). Receiver operating characteristic analysis found the percent changes of nRCBV and sRCBV at week 2 and sRCBV at week 16, but not rCBV data at week 8, to be good prognostic markers for OS-1. Patients with positive change from baseline rCBV had significantly shorter OS than those with negative change at both week 2 and week 16 (P = .0015 and P = .0067 for nRCBV and P = .0251 and P = .0004 for sRCBV, respectively). Early decreases in rCBV are predictive of improved survival in patients with recurrent GBM treated with bevacizumab.Keywords
This publication has 52 references indexed in Scilit:
- Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growthJournal of Experimental Medicine, 2012
- Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood PerfusionCancer Research, 2012
- Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysisBMC Cancer, 2010
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and miceNeuro-Oncology, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- The parametric response map is an imaging biomarker for early cancer treatment outcomeNature Medicine, 2009
- Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed gliomaJournal of Neuro-Oncology, 2009
- Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBMJournal of Neuro-Oncology, 2008
- Comparison of Dynamic Susceptibility-weighted Contrast-enhanced MR Methods: Recommendations for Measuring Relative Cerebral Blood Volume in Brain TumorsRadiology, 2008
- Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapyJournal of Neuro-Oncology, 2008